These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9457493)

  • 21. [Alpha-glucosidase inhibitor for type 2 diabetic patients. Clinical study with miglitol].
    Fehmann HC
    MMW Fortschr Med; 2000 May; 142(21):55. PubMed ID: 10872296
    [No Abstract]   [Full Text] [Related]  

  • 22. The effects of the intestinal glucosidase inhibitory BAY M 1099 (miglitol) on glycemic status of obese-diabetic rats.
    DeBouno JF; Michaelis OE; Tulp OL
    Gen Pharmacol; 1993 Mar; 24(2):509-15. PubMed ID: 8482529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Usefulness of miglitol in patients with diabetes mellitus type 2 and insufficient control of the blood glucose].
    de Luis Román DA; del Pozo García E; Aller R; Romero Bobillo E; Conde Valentín R
    Rev Clin Esp; 2004 Jan; 204(1):32-4. PubMed ID: 14746760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus.
    Sels JP; Kingma PJ; Wolffenbuttel BH; Menheere PP; Branolte JH; Nieuwenhuijzen Kruseman AC
    Neth J Med; 1994 Jun; 44(6):198-201. PubMed ID: 8052342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
    Segal P; Feig PU; Schernthaner G; Ratzmann KP; Rybka J; Petzinna D; Berlin C
    Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
    Johnston PS; Feig PU; Coniff RF; Krol A; Davidson JA; Haffner SM
    Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients.
    Aoki K; Nakamura A; Ito S; Nezu U; Iwasaki T; Takahashi M; Kimura M; Terauchi Y
    Diabetes Res Clin Pract; 2007 Oct; 78(1):30-3. PubMed ID: 17493703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of miglitol and acarbose on starch digestion, daily plasma glucose profiles and cataract formation.
    Madar Z; Hazan A
    J Basic Clin Physiol Pharmacol; 1993; 4(1-2):69-81. PubMed ID: 8679512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men.
    Aoki K; Kato H; Terauchi Y
    Endocr J; 2007 Dec; 54(6):1009-14. PubMed ID: 18048991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients.
    Johnston PS; Coniff RF; Hoogwerf BJ; Santiago JV; Pi-Sunyer FX; Krol A
    Diabetes Care; 1994 Jan; 17(1):20-9. PubMed ID: 8112185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Reducing postprandial glucose levels. Glucosidase antagonists].
    Neye H
    Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
    [No Abstract]   [Full Text] [Related]  

  • 32. [The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office].
    Fehmann HC
    Fortschr Med Orig; 2001 Jul; 119 Suppl 2():55-61. PubMed ID: 15704357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Miglitol: assessment of its role in the treatment of patients with diabetes mellitus.
    Campbell LK; Baker DE; Campbell RK
    Ann Pharmacother; 2000 Nov; 34(11):1291-301. PubMed ID: 11098345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.
    Ahr HJ; Boberg M; Brendel E; Krause HP; Steinke W
    Arzneimittelforschung; 1997 Jun; 47(6):734-45. PubMed ID: 9239452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. alpha-Glucosidase inhibition by miglitol in NIDDM patients.
    Kingma PJ; Menheere PP; Sels JP; Nieuwenhuijzen Kruseman AC
    Diabetes Care; 1992 Apr; 15(4):478-83. PubMed ID: 1499461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.
    Scott AR; Tattersall RB
    Diabet Med; 1988 Jan; 5(1):42-6. PubMed ID: 2964327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HbA(1c) and glycemic profile, basal- and post-treatment with Miglitol, in an area with a Mediterranean diet.
    Faure E; Pallardo LF; Mesa J; Puig-Domingo M; García-Mayor R; Benito P; Ravella R; Artés M; López JS;
    Diabetes Care; 2002 Oct; 25(10):1896-8. PubMed ID: 12351510
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of acarbose and miglitol (BAY-M-1099) on postprandial glucose levels following ingestion of various sources of starch by nondiabetic and streptozotocin-induced diabetic rats.
    Madar Z
    J Nutr; 1989 Dec; 119(12):2023-9. PubMed ID: 2695605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus.
    Reuser AJ; Wisselaar HA
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():19-24. PubMed ID: 8001622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The anti-diabetic drug miglitol is protective against anginal ischaemia through a mechanism independent of regional myocardial blood flow in the dog.
    Uno Y; Minatoguchi S; Arai M; Wang N; Chen XH; Hashimoto K; Lu C; Takemura G; Fujiwara H
    Clin Exp Pharmacol Physiol; 2005 Oct; 32(10):805-10. PubMed ID: 16173940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.